Register for our free email digests:
Shire BioChem Inc.
Division of Shire PLC
Latest From Arsenal AAA LLC
$1.4 billion in Q3 device financing was slightly lower than Q2's $1.8 billion with just one IPO versus Q2's seven. Acquisitions reached a high of $23 billion and diagnostics financing increased 30% over Q2 to $1 billion, while M&A activity at $1.2 billion showed a sharp decline from the previous quarter's $15.6 billion.
At $1.8 billion, Q2 device financing nearly doubled the Q1 total, mainly from an increase in IPOs and early VC rounds, and acquisitions were slightly higher at $4.7 billion. Diagnostics funding also increased to $784 million from Q1's $597 million, and Danaher's monster $13.8 billion buy of life sciences company Pall headlined the second quarter's $15.6 billion total in diagnostics M&A activity.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Medical Device Deals Update column is a survey of recent medtech M&A, alliance, and financing activity. This month’s column covers deals announced May-June 2015.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in June 2015.
- Drug Delivery
- Therapeutic Areas
- BioChem Pharma Inc.
- North America
- Parent & Subsidiaries
- Shire PLC
- Senior Management
Joseph Rus, Pres. & CEO
Frederick J Andrew, CFO
Gervais Dionne, PhD, EVP, R&D
Daniel Hetu, MD, VP, Corp. Dev.
- Contact Info
Shire BioChem Inc.
Phone: (514) 787-2300
2250 Alfred-Nobel Blvd.
Saint-Laurent, H4S 2C9
You must sign in to use this functionality
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.